ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
zonibon 100 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - zonisamid - 21 - antiepileptica, anticonvulsiva
zonibon 50 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - zonisamid - 21 - antiepileptica, anticonvulsiva
zonibon 25 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - zonisamid - 21 - antiepileptica, anticonvulsiva
rivaroxabán teva 20 mg filmom obalené tablety
teva gmbh, nemecko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
rivaroxabán teva 10 mg filmom obalené tablety
teva gmbh, nemecko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
rivaroxabán teva 2,5 mg filmom obalené tablety
teva gmbh, nemecko - rivaroxabán - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
sigletic 100 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 50 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 25 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)